Tisch Cancer Institute at Mount Sinai

 

i3 Health
Avatar

Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis

By i3 Health FEATURING John Mascarenhas
By i3 Health FEATURING John Mascarenhas
97 views
July 15, 2022
For more info, please visit https://bit.ly/3A3FmYr
Comments 0
Login to view comments. Click here to Login
Videos
05:46

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

121 views
11:06

ASH 2024 Insights: Ph3 BOREAS Study - Navtemadlin vs. Best Available…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

54 views
15:23

Non Immune-Based Approaches for Advanced Myeloma

Tisch Cancer Institute at Mount Sinai

G. Kaur

97 views
06:30

ASTRO 2023 Insights: "Treatment Landscape for mCRPC - Lu-177-PSMA, R…

Tisch Cancer Institute at Mount Sinai

W. Oh

203 views
10:51

SOHO 2023 Next Questions: Myeloproliferative Neoplasms

SOHO 2023 Eleventh Annual Meeting

J. Mascarenhas

67 views
17:34

SOHO 2023: Novel Non-JAK Inhibitor Therapies for Myelofibrosis

SOHO 2023 Eleventh Annual Meeting

J. Mascarenhas

233 views
01:07

Lecture Summary - WCLC 2022 on Cancer and Atopy: Parallel Drivers? I…

WCLC 2022 Conference Coverage

T. Marron

13 views
11:14

WCLC 2022 on Cancer and Atopy: Parallel Drivers? IL-4 Blockade Syner…

WCLC 2022 Conference Coverage

T. Marron

52 views
09:41

Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofi…

i3 Health

J. Mascarenhas

97 views
05:07

TKI in the Management of Advanced HCC

Icahn School of Medicine at Mount Sinai

A. Villanueva

237 views
11:42

Symptom Assessments in Myelofibrosis and How to Examine the Spleen

Icahn School of Medicine at Mount Sinai

M. Kremyanskaya

73 views
04:20

The Roles of Etiology and Biopsy in Hepatocellular Carcinoma

Oncology Data Advisor

A. Villanueva

34 views
20:43

PD-L1 Expression: Practical Implications in Advanced Stage NSCLC

Tisch Cancer Institute at Mount Sinai

F. Hirsch

198 views
07:13

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

165 views
06:20

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

117 views
05:04

ASCO GI 2022 Updates on IO for Early Stage HCC

ASCO GI 2022 Conference Coverage

A. Villanueva

173 views
15:25

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

ASH 2021 Conference Coverage on VuMedi

M. Kremyanskaya

92 views
07:56

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

57 views
05:15

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

622 views
21:07

Persistent Leukocytosis and PV Progression: Prognostic and Therapeut…

2021 International Congress on Myeloproliferative Neoplasms

J. Mascarenhas

18 views
01:47

2021 ASCO Summary on COVID-19 & Cancer

2021 ASCO Virtual Direct™ Highlights

D. Doroshow

10 views
08:32

2020 NSCLC Update: Does PD-L1 Predict Pembrolizumab Response in Pati…

Tisch Cancer Institute at Mount Sinai

D. Doroshow

166 views
06:49

Can Pacritinib Be Used to Treat Cytokine Storm in Patients With COVI…

Tisch Cancer Institute at Mount Sinai

J. Mascarenhas

3.1K views
28:34

Managing Hepatocellular Carcinoma: Early Detection and Diagnosis, St…

Tisch Cancer Institute at Mount Sinai

A. Villanueva

364 views
07:57

Epidemiology of Hepatocellular Carcinoma: Disease Burden and Trends

Tisch Cancer Institute at Mount Sinai

A. Villanueva

86 views
11:35

Clinical Challenges in Management of Hepatocellular Carcinoma: Liqui…

Tisch Cancer Institute at Mount Sinai

A. Villanueva

55 views
24:22

Update on Clinical Trials in Myeloproliferative Neoplasms

Tisch Cancer Institute at Mount Sinai

J. Mascarenhas

398 views